SCHEMBL6715907

SCHEMBL6715907

CSc1ccccc1NC(=O)C(c1ccccc1)N(C(=O)O)C(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.50
MEN1 O00255 6/20 0.50
CETP P11597 2/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 6/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
RAB9A P51151 4/20 0.43
NPC1 O15118 2/20 0.43
LMNA P02545 1/20 0.43
ALDH1A1 P00352 3/20 0.42
GAA P10253 1/20 0.42
TP53 P04637 2/20 0.42
MDM4 O15151 1/20 0.42
MDM2 Q00987 1/20 0.42
PKM P14618 1/20 0.41
ALOX15 P16050 1/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6716842 0.84 CYP1A2 (0.48) POLBMAPTSMN1; SMN2RAB9ANPC1
SCHEMBL6716835 0.84 CYP1A2 (0.48) POLBMAPTSMN1; SMN2RAB9ANPC1
SCHEMBL6716822 0.83 KCNQ2 (0.56) KMT2AMEN1POLBMAPTSMN1; SMN2
SCHEMBL6723623 0.82 POLB (0.51) KMT2AMEN1POLBMAPTLMNA
SCHEMBL6715819 0.81 POLB (0.49) KMT2AMEN1POLBSMN1; SMN2RAB9A
SCHEMBL6719510 0.81 MAPT (0.55) KMT2AMEN1POLBMAPTSMN1; SMN2
SCHEMBL6719501 0.81 MAPT (0.46) KMT2AMEN1POLBMAPTRAB9A
SCHEMBL6723567 0.80 L3MBTL1 (0.54) KMT2AMEN1SMN1; SMN2LMNAALDH1A1
SCHEMBL6717099 0.80 TSHR (0.53) KMT2APOLBMAPTSMN1; SMN2RAB9A
SCHEMBL6715913 0.80 MDM4 (0.41) KMT2AMEN1MAPTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 KMT2A 2020/4885MEN1 2933/4885CETP 1500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.